{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"}]}],"title":"Week 48 (n = 1937)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2"}]}],"title":"Week 96 (n = 1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9"}]}],"title":"Week 144 (n = 1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"}]}],"title":"Week 192 (n = 1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9"}]}],"title":"Week 264 (n = 1358)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"A major clinical response was defined as maintenance of an improvement of at least 70% in the American College of Rheumatology (ACR) score (ACR70) for at least 24 weeks. Improvement must be seen in tender (68 assessed joints) and swollen joint counts (66 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the left end of the scale \"no disease activity\" \\[symptom-free and no arthritis symptoms\\], right end of the scale \"maximum disease activity\"); patient assessment of pain in the previous 24 hours on a VAS (left end of the scale \"no pain\", right end of the scale \"unbearable pain\"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and erythrocyte sedimentation rate.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants Who Achieved a Major Clinical Response at Weeks 48, 96, 144, 192, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}